MDNA57 is our next generation IL-4 Empowered Cytokine™ (IL4-ECs) carrying a fully human cell killing payload. Whereas MDNA55 has the ability to efficiently target both, Type 1 and Type 2 IL-4R, MDNA57 has specific bias towards the Type 2 IL-4R, respectively.

MDNA57 provides a high degree of selectivity and is engineered to have a much better safety and efficacy profile. MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.